1229236-80-9 Usage
Description
(4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanon is a heterocyclic compound that belongs to the class of imidazo[1,2-b]pyridazine derivatives. It is characterized by the presence of halogen substituents in its chemical structure, which may contribute to its bioactivity. (4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanon has potential therapeutic applications and has been studied for its anti-cancer, anti-inflammatory, and anti-viral properties.
Uses
Used in Pharmaceutical Industry:
(4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanon is used as a potential therapeutic agent for various medical conditions due to its anti-cancer, anti-inflammatory, and anti-viral properties. The presence of halogen substituents in its chemical structure may enhance its bioactivity, making it a promising candidate for further research and development in the pharmaceutical industry.
Used in Cancer Research:
In the field of cancer research, (4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanon is used as a compound with potential anti-cancer properties. Its specific mechanisms of action and interactions with biological targets are still under investigation, but the compound's structure and properties suggest it may have potential applications in the development of new cancer treatments.
Used in Inflammation and Viral Infection Studies:
(4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanon is also used in the study of inflammation and viral infections. Its anti-inflammatory and anti-viral properties make it a candidate for further research in these areas, with the potential to contribute to the development of new treatments for inflammatory diseases and viral infections.
Further research is needed to fully understand the biological effects and potential uses of (4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanon, but its unique chemical structure and properties make it a promising compound for various applications in the pharmaceutical and medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1229236-80-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,9,2,3 and 6 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1229236-80:
(9*1)+(8*2)+(7*2)+(6*9)+(5*2)+(4*3)+(3*6)+(2*8)+(1*0)=149
149 % 10 = 9
So 1229236-80-9 is a valid CAS Registry Number.
1229236-80-9Relevant articles and documents
Development and a practical synthesis of the JAK2 inhibitor LY2784544
Mitchell, David,Cole, Kevin P.,Pollock, Patrick M.,Coppert, David M.,Burkholder, Timothy P.,Clayton, Joshua R.
, p. 70 - 81 (2012)
The route selection and process research and development of a practical synthesis for JAK2 inhibitor LY2784544 is described. The first-generation synthesis route, similar to that used in discovery for derivatization of a benzylic amine moiety, was 14 overall steps and possessed several steps that required extensive development for large-scale production. Route selection considerations led to a modified synthesis that utilized a novel vanadium-catalyzed carbon-carbon bond-forming arylation reaction for incorporation of the key benzylic morpholine moiety. A protecting group used to mask an amino pyrazole unit was modified from PMB to tert-butyl, resulting in a dramatic reduction in the overall length of the route. These two major changes resulted in an eight-step synthesis, which was six steps shorter than the first-generation synthesis. In the pilot plant, the new synthesis was scaled to produce >100 kg of LY2784544 in high yield and purity under GMP conditions. The overall development including the vanadium-catalyzed C-C bond-forming methodology, a ketone reductive deoxygenation, and a palladium-catalyzed amination is described.
AMINO PYRAZOLE COMPOUND
-
Page/Page column 4, (2010/06/22)
The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.
